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Abstract
Background: The diagnosis of Transient Ischaemic Attack (TIA) can be difficult and 50–60 % of patients seen in
TIA clinics turn out to be mimics. Many of these mimics have high ABCD2 scores and fill urgent TIA clinic slots
inappropriately. A TIA diagnostic tool may help non-specialists make the diagnosis with greater accuracy and
improve TIA clinic triage. The only available diagnostic score (Dawson et al) is limited in scope and not widely
used. The Diagnosis of TIA (DOT) Score is a new and internally validated web and mobile app based diagnostic
tool which encompasses both brain and retinal TIA.
Methods: The score was derived retrospectively from a single centre TIA clinic database using stepwise logistic
regression by backwards elimination to find the best model. An optimum cutpoint was obtained for the score.
The derivation and validation cohorts were separate samples drawn from the years 2010/12 and 2013 respectively.
Receiver Operating Characteristic (ROC) curves and area under the curve (AUC) were calculated and the diagnostic
accuracy of DOT was compared to the Dawson score. A web and smartphone calculator were designed subsequently.
Results: The derivation cohort had 879 patients and the validation cohort 525. The final model had seventeen
predictors and had an AUC of 0.91 (95 % CI: 0.89–0.93). When tested on the validation cohort, the AUC for DOTS
was 0.89 (0.86–0.92) while that of the Dawson score was 0.77 (0.73–0.81). The sensitivity and specificity of the
DOT score were 89 % (CI: 84 %–93 %) and 76 % (70 %–81 %) respectively while those of the Dawson score were
83 % (78 %–88 %) and 51 % (45 %–57 %). Other diagnostic accuracy measures (DOT vs. Dawson) include positive
predictive values (75 % vs. 58 %), negative predictive values (89 % vs. 79 %), positive likelihood ratios (3.67 vs. 1.70) and
negative likelihood ratios (0.15 vs. 0.32).
Conclusion: The DOT score shows promise as a diagnostic tool for TIA and requires independent external validation
before it can be widely used. It could potentially improve the triage of patients assessed for suspected TIA.
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Background
The diagnosis of transient ischaemic attack (TIA) can
be difficult and studies show limited inter-observer
agreement for clinical diagnosis [1]. About 50 to 60 %
of TIA referrals by non- specialists turn out to be non-
cerebrovascular mimics [2–4]. Patients with TIA have a
high risk of early stroke and subsequent adverse events
[5, 6]. Following secondary prevention studies [7, 8]
and the introduction of the ABCD2 score [9], rapid
assessment TIA clinics have been set up to investigate
and manage TIA. Inappropriate referrals to TIA clinics,
however, can lead to delays for patients with TIA and
the misdiagnosis of non -cerebrovascular conditions as
TIA leads to unnecessary anxiety and inappropriate ini-
tial management.
Stroke diagnostic tools such as FAST and ROSIER
have been developed for use by pre hospital assessors
and emergency room clinicians [10, 11]. The ABCD2
score, too, has been used as a crude diagnostic aid for
TIA [12]. More recently, the ability of the ABCD2 score
to reliably discriminate between those at high or low risk
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after a TIA has been called into question and a third of
mimics found to have ABCD2 scores ≥ 4 [13]. A TIA
diagnostic tool could be used to improve TIA clinic tri-
age by removing some mimics from urgent TIA path-
ways. There is only one TIA diagnostic tool, the score of
Dawson and colleagues [14] which was not designed for
retinal and some posterior circulation events and is not
widely used. It has shown limited accuracy when used in
a primary care setting [15]. The Diagnosis of TIA Score
(DOTS) is a new tool to help non-specialists make the
diagnosis of TIA with greater accuracy. It includes ret-
inal and posterior circulation events and is meant for
use as a mobile app and web based calculator.
Methods
Development cohort
The development cohort for the score was a subset of
TIA clinic patients studied retrospectively from a TIA
database [2]. Briefly, all patients referred to the Monday
to Friday TIA clinics of Gloucestershire Royal Hospital
(GRH), Gloucester, UK between April 2010 and May
2012 were eligible for inclusion in the development co-
hort. The catchment area for GRH has a population of
560,000. Referrals are accepted from Emergency Depart-
ments, General Practitioners, paramedics and other de-
partments such as ophthalmology.
Data collected included demographic information, past
medical history, a detailed history, examination findings,
ABCD2 scores, results of investigations (blood tests,
ECG, same day carotid duplex ultrasounds, same day
CT brain scans) and final diagnosis [2]. MRI scans were
not done on the same day but later as required. The
diagnosis was made by consultant stroke physicians with
at least 7 to 10 years of stroke experience. Patients were
classified as TIA, minor stroke or mimic. TIA was de-
fined as an acute loss of focal cerebral or ocular function
lasting < 24 h and presumed to be caused by embolic or
thrombotic vascular disease while a stroke was diag-
nosed if symptoms lasted > 24 h [16, 17]. A diagnosis of
stroke was also made if symptoms lasted < 24 h but there
was a new infarct visible on CT [18]. The minor strokes
in this cohort were patients who had minimal symptoms
or signs and did not require hospital admission. TIAs
and strokes included retinal as well as cerebral events.
The traditional NINDS diagnostic criteria [19] for TIA
were used with a few exceptions at the discretion of the
diagnosing physician. In the absence of a gold standard
for diagnosis and lack of same day diffusion weighted
MRI, to make the clinic diagnosis more robust, follow
up data for a median of 34.9 months (IQR 27.7 – 41.6)
were accessed to look at subsequent vascular events and
death [2]. In a small number of cases, the final diagnosis
was altered based on new information from follow up.
Ethics, consent and permissions
The study had the necessary institutional permission
from the Gloucestershire Hospitals NHS Foundation
Trust (GHNHSFT). It was reviewed by the funding Re-
search and Innovation Forum of the GHNHSFT and
Gloucestershire Research Support Service (GRSS) with
regards to the appropriate IRB/Ethical reviews necessary.
The study was assessed as requiring no Research Ethics
Committee/IRB review or formal patient consent. The
basis for this decision, as per the regulations of the UK
Health Departments Governance Arrangements for Re-
search Ethics Committees, was that the study was lim-
ited to secondary use of information previously collected
in the course of normal clinical care and that the no pa-
tient identifiers were recorded in the dataset for analysis.
No patient contact or additional procedures were neces-
sary for this study.
Statistical analysis
Selection of variables for analysis
Information derived from the history were coded into
discrete binary variables such as “unilateral weakness”,
“dysphasia”, “dysarthria”, “headache”, “amnesia” etc.
These variables were selected from clinical features ex-
pected to predict stroke or TIA based on previous
experience as well as those likely to favour mimics such
as migraine and seizures [10, 11, 14, 19, 20]. Age and
risk factors were other potential predictors. Preliminary
univariate analysis was used to identify predictive vari-
ables although non- significant variables were not ex-
cluded automatically from fitted models.
Logistic regression and model selection
The dependent variable was “definite cerebrovascular
disease” which included TIAs and minor strokes of the
brain or eye. Stepwise multiple logistic regression using
the backwards elimination method was performed to se-
lect the best model using the Akaike information criter-
ion [21].
The actual score
The diagnostic score was derived from the coefficients
of the final model and the intercept [21]. Calibration of
the models was tested by calibration plots and the
Hosmer-Lemeshaw statistic and discrimination by Re-
ceiver Operating Characteristic (ROC) curves and area
under the curve (AUC or c statistic) [22]. Optimal cut-
points for the score were derived from the ROC curve
using two methods; criteria based on sensitivity and spe-
cificity alone using the Youden Index and the cost of
misclassification method (cost benefit analysis of diagno-
sis) where an assumption of a 2:1 cost ratio was made
(i.e. the cost of misclassifying a TIA as a mimic is twice
that of misclassifying a mimic as a TIA) [23]. Specificity,
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sensitivities and other measures of diagnostic accuracy
were calculated for each cut point [24]. A web based
calculator and smartphone app were subsequently de-
signed to calculate the logit, probability of the outcome
and to present the result as “probable TIA”, “possible
TIA” or “TIA unlikely.
Although no formal sample size calculation was under-
taken, the rule of thumb to satisfy the requirements for
developing a score by logistic regression modelling was
met by using the available sample; there were more than
10–20 outcome events per potential predictor variable
studied [25, 26].
Internal validation
A separate validation cohort of patients was taken from
patients referred to the GRH TIA clinic from January to
August 2013. Baseline characteristics of the derivation
and validation cohorts were compared using the t-test
and chi-squared test. The DOTS and Dawson score [14]
were calculated retrospectively by one observer blinded
to the clinic diagnosis. The clinic diagnosis, made by a
stroke consultant, was accepted as the gold standard.
Predicted and observed diagnoses were plotted to test
calibration and discrimination was tested by the c statis-
tic with 95 % CI. The c statistic for ABCD2 scores (as
recorded by the referring clinicians) and Dawson scores
were also calculated and ROC curves compared. Data
were analysed using “R” [27].
Results
The derivation dataset was a subset of 1067 patients [2].
Of the 1067 records, 188 records were rejected as the
initial history had been recorded by trainee doctors or
specialist nurses and not experienced stroke consultants.
Data for 879 patients were satisfactory in every respect
and used as the training dataset. In 12 out of 879 pa-
tients, the final diagnosis was altered based on new in-
formation from follow up.
The validation cohort comprised 525 separate pa-
tients referred between January and August 2013.
Table 1 shows the baseline characteristics of the devel-
opment and validation datasets. Of patients with stroke
or TIA in the development cohort, 65 % had anterior
circulation events, 16 % posterior circulation and 19 %
retinal events. The validation cohort had 70 % anterior
circulation, 13 % posterior and 17 % retinal events. The
two cohorts were different in many respects including
the proportion of minor strokes, presence of previous
vascular disease, hypertension, diabetes and atrial fibril-
lation (AF).
The initial logistic regression model included the fol-
lowing predictors; age, sex, AF, hypertension, previous
cerebrovascular disease, diabetes, other vascular dis-
ease (including ischaemic heart disease and peripheral
vascular disease), dysphasia, dysarthria, facial weakness,
unilateral weakness (arm, leg or both), sensory loss,
monocular visual loss, diplopia, bilateral visual loss,
hemianopia, visual aura (scintillations, fortification
spectra or spreading scotoma), dizziness, vertigo, ataxia
(either limb, gait or both), headache, confusion, tin-
gling/numbness (face or limbs), amnesia, seizure (de-
fined as any rhythmical involuntary movement) and
loss of consciousness or near loss of consciousness.
After the stepwise selection process, during which 9
different models were assessed, the following variables
were left in the final model: age, history of hyperten-
sion, history of AF/new onset AF and fourteen clinical
features as shown in Table 2, which lists the coeffi-
cients, standard errors odds ratios with 95 % confi-
dence intervals of each predictor in the model. The
intercept of the final model was -3.365. All the vari-
ables were significant at a level of p <0.05 (many sig-
nificant at p <0.001) except for hypertension. The only
continuous predictor was age and an assumption of
linearity was made for this predictor. The optimal cut
point for the score was 0.297 using the Youden Index
and – 0.547 using the cost of misclassification method.
The calculated sensitivity using a cutpoint of 0.297 was
84 % and specificity 85 % while the cutpoint – 0.547 gave
a sensitivity of 93 % and specificity of 74 %. This cutpoint
(-0.547) was the one used in the final score and calculators
to differentiate between non-TIA and possible or probable
TIA. Patients with a DOT score ≥ 0.297 (probability of
TIA > 57.4 %) were classified as “Probable TIA” with those
between -0.547 and 0.297 classified as “Possible TIA” and
those with a DOT score of < - 0.547 (probability of TIA <
36.7 %) were classed as “TIA unlikely” (Additional file 1).
Figure 1 shows the calibration plots (predicted vs ob-
served results) of the final model on the derivation and
validation cohorts. The P value was 0.273 for the Hosmer-
Lemeshow test of goodness of fit in the derivation sample.
As would be expected, the plots show better calibration
for the derivation than validation datasets.
The c statistic (AUC) was 0.91 (95 % CI: 0.89 - 0.93)
for the final model on the derivation cohort. Figure 2
compares the ROC curves drawn to assess discrimin-
ation of the DOTS, Dawson and the ABCD2 scores
when applied to the full validation cohort and the val-
idation cohort excluding retinal events (n = 485). The
c statistic with confidence intervals are shown. Both the
DOT and Dawson scores showed good discrimination.
Table 3 shows the actual numbers of positive and
negative diagnoses and several diagnostic accuracy mea-
sures using the DOT score (with two alternative cut-
points) and the Dawson score tested on the validation
dataset. As the Dawson score was not originally designed
for retinal events, all test parameters for the DOT and
Dawson scores were repeated using the validation dataset
Dutta BMC Neurology  (2016) 16:20 Page 3 of 7
excluding retinal vascular events (n = 485). These results
are also shown in Table 3.
In the 24 patients in whom the DOT score wrongly
missed TIAs or strokes, 15 were anterior circulation
events, eight posterior circulation and one was a retinal
TIA. However, only 7/24 (29 %) had some imaging (CT,
MR or carotid) abnormalities in keeping with cerebro-
vascular disease. Many of the histories in this group of
patient were atypical with non -focal as well as focal
features and the diagnoses were recorded as probable
or possible TIA /stroke suggesting some diagnostic
uncertainty.
Discussion
The DOT score is a new TIA diagnostic tool which per-
formed well in comparison to the Dawson score [14]
when applied to the validation dataset. The sensitivities
were very similar in the two scores but other measures
such as specificity, positive and negative predictive
values and AUC were superior for DOTS. Unlike the
Table 1 Characteristics of the developmental and validation datasets
Development cohort (n = 879) Validation cohort (n = 525) P values
Age in years (mean, SD(standard deviation) 69.3 (13.8) 70.8 (14.0) 0.051
Sex (proportion of females) 50.4 % 54.1 % 0.198




Proportion of TIA 272 (30.9 %) 160 (30.5 %) 0.901
Proportion of stroke 174 (18.7 %) 76 (14.5 %) 0.014
Proportion of mimics 443 (50.4 %) 289 (55.1 %) 0.103
Previous cerebrovascular disease 128 (14.6 %) 32 (6.1 %) < 0.001
Hypertension 365 (41.5 %) 106 (20.2 %) < 0.001
Diabetes 117 (13.3 %) 27 (5.2 %) < 0.001
AF 101 (11.2 %) 25 (4.8 %) < 0.001
Smoker 165 (18.8 %) 24 (4.6 %) < 0.001
GP, general practitioner, ED, emergency department
Table 2 Predictors in the final model with coefficients, standard errors (SE), Odds Ratios and 95 % Confidence Intervals. The
intercept was -3.365
Predictor Regression coefficients (SE) Odds Ratios 95 % CI
Age 0.02 (0.01) 1.0 1.0–1.03
History of hypertension 0.32 (0.20) 1.4 0.9–2.0
History of AF or new AF 0.62 (0.32) 1.7 1.0–3.5
Dysphasia 3.13 (0.30) 22.9 12.8–42.5
Unilateral facial weakness (UMN) 1.69 (0.35) 5.4 2.7–11.0
Unilateral weakness (arm, leg or both) 3.15 (0.28) 23.3 13.6–41.2
Monocular visual loss 3.58 (0.35) 35.8 18.3–73.2
Diplopia 2.14 (0.56) 8.5 2.9–26.4
Bilateral visual loss 1.83 (0.52) 6.2 2.2–17.2
Hemianopia 3.25 (0.56) 25.8 9.0–81.1
Visual aura (fortification spectra, scintillations or spreading scotoma) −1.84 (0.35) 0.2 0.1–0.3
Unilateral sensory loss 2.11 (0.95) 8.2 1.4–67.4
Ataxia (limb or gait) 2.06 (0.37) 7.9 3.9–16.6
Headache −0.66 (0.25) 0.5 0.3–0.8
Amnesia −1.70 (0.62) 0.2 0.04–0.6
Loss of consciousness or pre-syncope −0.78 (0.39) 0.5 0.2–1.0
Tingling/numbness/pins and needles −0.80 (0.26) 0.5 0.3–0.7
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Dawson score, this score attempts to encompass the en-
tire spectrum of TIA/stroke that would be expected in a
TIA clinic including brain (anterior and posterior circu-
lation) and retinal events. In contrast to a previous
study, the ABCD2 scores, which were those recorded by
the referring clinician, showed very poor discrimination
for the diagnosis of TIA [12]. This suggests, in keeping
with a recent meta-analysis [13], that clinic triage based
on non-specialist use of the ABCD2 score could be im-
proved by the use of a diagnostic score to enable quicker
assessment of patients with a higher a priori probability
of TIA or minor stroke.
Seizure and dysarthria are two seemingly surprising
omissions from the final model. There were only 18 pa-
tients with overt rhythmical movements in the deriv-
ation cohort (of which at least one had limb shaking
TIA) and other potentially postictal features like amnesia
and loss of consciousness were significant. In contrast to
some other scores [10, 11, 14], the DOT score attempts
to distinguish between dysphasia and dysarthria to im-
prove its specificity. It is well known that dysarthria has
a broader differential diagnosis and, particularly in isola-
tion, does not necessarily suggest a TIA. Other common
cerebrovascular symptoms which are often associated
with dysarthria were significant in the final model sug-
gesting that the omission of dysarthria may not affect
the sensitivity of the score. Many patients with transient
monocular visual loss in the derivation cohort had been
referred by the ophthalmology department and so alter-
native diagnoses may have been screened out leading to
a higher preponderance of ocular TIA in this group of
patients. The recommendation that all patients with vis-
ual loss should have other ocular pathology excluded
before attributing the visual loss to a TIA, therefore ex-
tends to the presumed diagnosis of retinal TIA based on
this score. It is also necessary to emphasise that patients
Fig. 1 Calibration plots for the final DOT model on the derivation and validation cohorts
Fig. 2 ROC curves for the DOT, Dawson and ABCD2 scores on the full validation cohort (n = 525) and on the validation cohort excluding
retinal events (n = 485)
Dutta BMC Neurology  (2016) 16:20 Page 5 of 7
with ongoing neurological signs or symptoms or any ap-
propriate lesion on imaging should be considered as
having a stroke and managed accordingly.
It has been suggested that it is unrealistic for a clinical
scoring system to cover all types of TIA given the het-
erogeneity of their symptoms [14]. However, this score
was derived from a TIA cohort with a typical case-mix
of anterior, posterior and retinal events as well as a high
proportion of mimics. This explains why the score is not
“parsimonious” and includes 17 items; more predictors
are needed to sort TIA from mimics given their varied
symptoms. A model as complex as this can be consid-
ered impractical but becomes highly usable when pre-
sented as a calculator or mobile app. Once the history is
taken, using the web calculator or app takes about 30 s.
This approach also enables guidance notes to be incor-
porated in the tool to help non- specialist assessors
select the appropriate predictors with greater accuracy.
It is well known that predictive tools derived in one
health care setting may not translate well to others. It is
hoped, however, that the guidance provided will preserve
the score’s predictive performance when it is used by
primary care or emergency department physicians.
The sample size used to derive the DOT score may
not be considered large but it met the essential require-
ments of developing a score by logistic regression mod-
elling [25, 26]. Although same day DWI-MR was not
available, diagnosis was made by experienced stroke
physicians mostly using standard NINDS diagnostic cri-
teria [19]. Results of follow up were taken into account
to refine the diagnoses made. The dataset for the deriv-
ation cohort was complete in every respect. Validation,
although internal and retrospective used a separate set
of patients from a different time point which differed in
many respects from the derivation cohort. The DOT and
Dawson scoring was done by one observer blinded to the
clinic diagnosis. The difference in the two cohorts was
probably due to chance alone and strengthens the external
validity of the DOT score. The case-mix suggests that the
score should be generalizable to all TIA services which
accept unselected patients referred by primary care physi-
cians, emergency or other departments.
Table 3 Diagnostic accuracy of DOT (cutpoint 0.297), DOT (cutpoint – 0.547) and Dawson scores on full validation cohort and
cohort excluding retinal events. Confidence intervals (95 %) are shown where available
Full validation cohort (n = 525)
DOT 0.297 DOT -0.547 Dawson
True positive 192 210 197
False positive 41 70 142
True negative 248 219 147
False negative 44 26 39
Sensitivity 81 % (76 %–86 %) 89 % (84 %–93 %) 83 % (78 %–88 %)
Specificity 86 % (81 %–90 %) 76 % (70 %–81 %) 51 % (45 %–57 %)
Positive predictive value 82 % (77 %–87 %) 75 % (70 %–80 %) 58 % (53 %–63 %)
Negative predictive value 85 % (80 %–89 %) 89 % (85 %–93 %) 79 % (72 %–85 %)
Positive likelihood ratio 5.73 (4.29–7.66) 3.67 (2.98–4.53) 1.70 (1.49–1.94)
Negative likelihood ratio 0.22 (0.17–0.28) 0.15 (0.10–0.21) 0.32 (0.24–0.44)
Validation cohort excluding retinal events (n = 485)
DOT 0.297 DOT -0.547 Dawson
True positive 156 172 175
False positive 41 70 142
True negative 248 219 147
False negative 40 24 21
Sensitivity 80 % (73 %–85 %) 88 % (82 %–92 %) 89 % (84 %–93 %)
Specificity 86 % (81 %–90 %) 76 % (70 %–81 %) 51 % (45 %–57 %)
Positive predictive value 79 % (73 %–85 %) 71 % (65 %–77 %) 55 % (50 %–61 %)
Negative predictive value 86 % (82 %–90 %) 90 % (86 %–94 %) 88 % (82 %–92 %)
Positive likelihood ratio 5.61 (4.19–7.51) 3.62 (2.94–4.47) 1.82 (1.60–2.06)
Negative likelihood ratio 0.24 (0.18–0.31) 0.16 (0.11–0.24) 0.21 (0.14–0.32)
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Conclusion
In conclusion, the DOT score shows promise as an use-
ful tool for the diagnosis of TIA which will require ex-
ternal validation before it can be widely used. Impact
studies would also be necessary to show that the score
improves TIA clinic triage.
Additional file
Additional file 1: Online supplement DOTS Calculator. (html 20.5 kb)
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